Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil

Core Insights - Merck & Co reported higher third quarter revenue driven by the growth of its cancer drug Keytruda, which compensated for declining sales of the human papillomavirus vaccine Gardasil in China [1] Group 1 - The increase in revenue is attributed to the strong performance of Keytruda, a blockbuster cancer treatment [1] - Sales of Gardasil have been falling, particularly in the Chinese market, impacting overall revenue [1]